duvelisib · Secura · NDA 211155
Copiktra
Earliest generic entry, as listed · earliest of 2 marketed strengths
26 Apr 2035
Blocked by patent: US 12213983. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12213983 | use U-2412 | 26 Apr 2035 |
| US 8193182 | substance | 24 Sep 2032 |
| US RE46621 | substance, product | 17 May 2032 |
| US 11312718 | product | 10 Jan 2032 |
| US 9840505 | use U-2412 | 10 Jan 2032 |
| US 9840505 | use U-2413 | 10 Jan 2032 |
| US 9216982 | use U-2413 | 5 Jan 2029 |
| US 9216982 | use U-2412 | 5 Jan 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211155 · 001 · RLD | capsule, oral | 15MG | 26 Apr 2035 |
| 211155 · 002 · RLD | capsule, oral | 25MG | 26 Apr 2035 |